VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe
Valneva receives marketing authorization in Europe for inactivated whole-virus COVID-19 vaccine VLA2001 Valneva , a specialty vaccine company, today announced... View Article
Valneva receives marketing authorization in Europe for inactivated whole-virus COVID-19 vaccine VLA2001
VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe Valneva, a specialty vaccine company, today... View Article
Valneva announces settlement agreement with the UK Government
Valneva, a specialty vaccine company, today announced that it has entered into a settlement agreement with the Government of the... View Article
OSE Immunotherapeutics announces collaboration with Microsoft
OSE selected by Microsoft France to join the “Biotech Scaler Program” launched during “Viva Technology”, the European Startup and Tech... View Article
Safety and efficacy results of LIS1, a new induction treatment in organ transplantation by the French biotech XENOTHERA
Results from the clinical trial of LIS1, XENOTHERA’s polyclonal glyco-humanised antibody and induction immunosuppressant in solid organ transplantation, were presented... View Article
Owkin announces multi-year clinical data science strategic collaboration with Bristol Myers Squibb
Owkin announced that it has entered into a multi-year, strategic collaboration with Bristol Myers Squibb to apply Owkin’s Artificial Intelligence... View Article
EMA accepts filing of marketing authorization application for Valneva’s inactivated COVID-19 vaccine candidate
Valneva, a specialty vaccine company, confirmed that the European Medicines Agency (“EMA”) has accepted the filing of a marketing authorization... View Article
Promega and Stilla announce co-marketing agreement to offer complete digital PCR workflow solution
Promega Corporation – member of Atlanpole Biotherapies and leader in providing innovative solutions and technical support to the life sciences industry, and... View Article
ALGOSOURCE announces the recruitment of the first patient in the PROPERTY clinical trial for the PHYCOCARE® product and accelerates its clinical nutraceutical program to support digestive cancer therapies
The world’s first clinical nutraceutical program based on microalgae A breakthrough innovation in the therapeutic management of digestive cancers The... View Article
Hemarina helps to heal injuries in reconstructive surgery with HEMO2life® oxygen carrier
During his visit to France’s Percy Army Training Hospital on 28 April 2022, The French President met several soldiers who... View Article